A preliminary study on cause‑of‑death discrimination and the pathological stage identification in acute ischemia heart disease (AIHD) based on plasma lipidomic technique and machine learning algorithms.

Journal: International journal of legal medicine
Published Date:

Abstract

The sudden death discrimination of acute ischemia heart disease (AIHD) and the determination of the AIHD pathological stage are the difficulties in forensic medicine. More potential biomarkers with high sensitivity and specificity still need to be identified to diagnose AIHD. Current studies have linked concentration variation in lipid characteristics after death to the identification of causes of death, providing a potential strategy for diagnosing AIHD. In this study, we used ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS/ MS) to systematically analyze the non-targeted lipid metabolism profile of the corpse blood of AIHD and non-cardiac disease death cases. A total of 665 lipid metabolites were detected. The study rigorously analyzed the performance of 8 cutting-edge machine learning algorithms in accurately identifying AIHD. We identified 18 lipid metabolites for AIHD discrimination and 47 for early myocardial ischemia (EMI) and acute myocardial infarction (AMI) identification according to the feature importance. We developed an e-Xtreme gradient boosting (XGB) optimized classification model (AUC = 0.830, Accuracy = 0.781) and a logistic regression (LR) optimized model (AUC = 0.990, Accuracy = 0.964). Our results demonstrate the potential application of plasma lipidomic technique combined with machine learning in diagnosing the cause of death and determining the pathological stage of AIHD.

Authors

  • Xing-Yu Ma
    Collaborative Innovation Center of Judicial Civilization, Key Laboratory of Evidence Science, Ministry of Education, China University of Political Science and Law, Beijing 100088, China.
  • Can-Can Sun
    Institute of Systems Biomedicine, Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
  • Tian-Qi Wang
    Collaborative Innovation Center of Judicial Civilization, Key Laboratory of Evidence Science, Ministry of Education, China University of Political Science and Law, Beijing, 100088, China.
  • Qi Wang
    Biotherapeutics Discovery Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Guang-Xi Wang
    Institute of Systems Biomedicine, Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, China.
  • Jiao Liu
  • Dong Zhao
    Collaborative Innovation Center of Judicial Civilization, Key Laboratory of Evidence Science, Ministry of Education, China University of Political Science and Law, Beijing 100088, China.